Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label Replagal study in treatment-naive Fabry disease
2018-004689-32Phase 3Terminated
- Sponsor
- Takeda
- Start
- Aug 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of agalsidase alfa in Fabry disease (FD), sponsored by Takeda. Primary endpoints: Estimated glomerular filtration rate and Left ventricular mass index. Started Aug 2021; status: terminated.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2018-004689-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004689-32.